Analyst Upgrades This Stock And Doubles Price Target On Encouraging Ibsrela Story
After the market close Thursday, Ardelyx Inc (NASDAQ:ARDX) reported Q4 FY22 Ibsrela sales of $8.7 million and $15.6 million for FY22. The…
How Much Did US Government Spend On mRNA Vaccine Technology Before And During The Pandemic? The Number Can Be Surprising
The U.S. government invested at least $31.9 billion to develop, produce, and purchase mRNA COVID-19 vaccines, including sizeable…
Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo
Exelixis Inc (NASDAQ:EXEL) announced that the phase 3 CONTACT-03 study did not meet its primary endpoint of progression-free survival (PFS). CONTACT-03 is…
Why Veru Stock Is Crashing Today?
The FDA declined to grant Veru Inc’s (NASDAQ:VERU) request for Emergency Use Authorization (EUA) for sabizabulin to treat hospitalized adult patients…
Despite Trial Failure Praxis Still Seeks Advancing Essential Tremor Program Into Phase 3 Study
Praxis Precision Medicines Inc (NASDAQ:PRAX) announced topline results from the Essential1 study evaluating the efficacy, safety, and tolerability of ulixacaltamide (PRAX-944)…
Alpha Tau Announces Grant Of Expanded Radioactive License And Final Pre-Clinical Laboratory Regulatory Approval At Its Jerusalem Headquarters
Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that the Israeli
Praxis Precision Medicines’s Essential1 Study Evaluating Ulixacaltamide (PRAX-944) For Essential Tremor Did Not Reach Statistical Significance On Primary Endpoint, Change From Baseline To Day 56 In The Modified Activities Of Daily Living (mADL) Score
Ulixacaltamide demonstrated improvement in modified Activities of Daily Living (mADL) primary efficacy endpoint relative to placebo that did not reach statistical significance (p=0.126), and achieved nominal
Incannex Has Engaged Catalent To Develop And Manufacture A cGMP-grade Psilocybin Drug Product For Use In Incannex’s Proprietary Psilocybin-assisted Psychotherapy Drug Development Program And, Potential Wider Commercial Use
Commencing development and manufacture of a psilocybin drug product follows an internal analysis of the interim data from the PsiGAD phase 2 clinical trial, giving Incannex confidence to proceed with formulation
The European Commission Has Approved Bristol Myers Squibb’s Reblozyl (Luspatercept) For Anemia Associated With Non-transfusion-dependent Beta-thalassemia
The EC approval of Reblozyl was based on results from the Phase 2 BEYOND study, evaluating the efficacy and safety of Reblozyl versus placebo in 145 adults with NTD beta thalassemia. Patients were
Verve Therapeutics Reported New Preclinical Data In Non-human Primates Demonstrating Potent, Durable, And Well-tolerated Editing Of The ANGPTL3 Gene Following The Administration Of VERVE-201
VERVE-201 aims to reduce the heavy treatment burden associated with available therapies for HoFH including the requirement for multiple oral, injectable, and intravenous infusions in each patient, often administered over